Skip to content

Serotonin research published in 2006

30 studies whose primary subject is serotonin were published in 2006, up from 26 in 2005. Newest first. Back to the serotonin overview

Studies

The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats.

Psychopharmacology December 1, 2006 Kirsten Krebs-Thomson, Erbert M Ruiz, Virginia L Masten et al. 96 citations

The hallucinogen 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is structurally similar to other indoleamine hallucinogens such as LSD. The present study examined the effects of 5-MeO-DMT in rats using the Behavioral Pattern Monitor (BPM), which enables analyses of patterns of locomotor activity and exploration, and the prepulse inhibition of startle (PPI) paradigm. A series of interaction...

The effect of polymorphism at the serotonin transporter gene on decision-making, memory and executive function in ecstasy users and controls.

Psychopharmacology October 2006 Jonathan P. Roiser, Robert D Rogers, Lynnette J Cook et al.

3, 4-Methylenedioxymethamphetamine (MDMA or "ecstasy") is a popular drug of abuse known to result in depletions of the serotonin (5-HT) system. A number of studies have reported that ecstasy users differ from controls on a variety of measures of cognitive function. However, the literature is not consistent and many negative findings were also reported. One reason for such inconsistency might be...

1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists.

Journal of Medicinal Chemistry September 21, 2006 Thomas H. Mclean, Jason C. Parrish, Michael R Braden et al. 115 citations

A series of conformationally restricted analogues of the hallucinogenic phenethylamine 1 (2,5-dimethoxy-4-bromophenethylamine, 2C-B) was synthesized to test several hypotheses concerning the bioactive conformation of phenethylamine ligands upon binding to the 5-HT(2A) receptor. These benzocycloalkane analogues were assayed for their receptor binding affinity and ability to activate downstream...

DOI: 10.1021/jm060656o (opens in new tab) Full text (opens in new tab) LSD Psychopharmacology: neuropharmacology Drug action Brain chemistry +15

Serotonin 5‐HT2A receptor activation induces 2‐arachidonoylglycerol release through a phospholipase c‐dependent mechanism

Journal of Neurochemistry August 15, 2006 Jason C. Parrish, David E. Nichols 61 citations

To date, several studies have demonstrated that phospholipase C-coupled receptors stimulate the production of endocannabinoids, particularly 2-arachidonoylglycerol. There is now evidence that endocannabinoids are involved in phospholipase C-coupled serotonin 5-HT(2A) receptor-mediated behavioral effects in both rats and mice. The main objective of this study was to determine whether activation...

DOI: 10.1111/j.1471-4159.2006.04173.x (opens in new tab) Serotonin 2-arachidonoylglycerol Endocannabinoid system Phospholipase c +8

Neural Effects of MDMA as Determined by Functional Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy in Awake Marmoset Monkeys

Annals of the New York Academy of Sciences August 1, 2006 Jerrold S. Meyer, Matthew E. Brevard, Brian J. Piper et al. 40 citations

Abstract: We used functional magnetic resonance imaging (fMRI) to investigate the acute effects of a recreational dose (1 mg/kg p.o.) of 3,4‐methylenedioxymethamphetamine (MDMA) on regional brain activity in awake, restrained marmoset monkeys. In a second study, magnetic resonance spectroscopy (MRS) and postmortem measurements of serotonin transporter (SERT) binding and serotonin (5‐HT)...

MDMA in Adolescent Male Rats

Annals of the New York Academy of Sciences August 1, 2006 Raquel Faria, Ana Magalhães, Pedro Monteiro et al. 29 citations

Abstract: Long‐term behavioral consequences of the neurotoxicity produced by 3,4‐methylenedioxymethamphetamine (MDMA) in the adolescent rat are still mostly unknown. Here, adolescent male rats (postnatal day 45 PND [45]) were exposed to 10 mg/kg of MDMA, intraperitoneally, every 2 h for 6 h. Controls were given 0.9% saline in the same protocol. Ten days after exposure, the behavioral effects of...

Persistent cerebrovascular effects of MDMA and acute responses to the drug

European Journal of Neuroscience July 1, 2006 Linda Ferrington, Eszter Kirilly, Douglas E. Mcbean et al. 21 citations

Abstract Acutely, 3,4,‐methylenedioxymethamphetamine (MDMA) induces cerebrovascular dysfunction [ Quate et al ., (2004) Psychopharmacol. , 173 , 287–295]. In the longer term the same single dose results in depletion of 5‐hydroxytrptamine (5‐HT) nerve terminals. In this study we examined the cerebrovascular consequences of this persistent neurodegeneration, and the acute effects of subsequent...

C-(4,5,6-Trimethoxyindan-1-yl)methanamine: A Mescaline Analogue Designed Using a Homology Model of the 5-HT2AReceptor

Journal of Medicinal Chemistry June 21, 2006 Thomas H. Mclean, James J. Chambers, Jason C. Parrish et al. 24 citations

A conformationally restricted analogue of mescaline, C-(4,5,6-trimethoxyindan-1-yl)-methanamine, was designed using a 5-HT(2A) receptor homology model. The compound possessed 3-fold higher affinity and potency than and efficacy equal to that of mescaline at the 5-HT(2A) receptor. The new analogue substituted fully for LSD in drug discrimination studies and was 5-fold more potent than mescaline....

DOI: 10.1021/jm060272y (opens in new tab) Mescaline Potency Stereochemistry Homology modeling +8

MDMA‐induced neurotoxicity: long‐term effects on 5‐HT biosynthesis and the influence of ambient temperature

British Journal of Pharmacology June 12, 2006 Esther O’shea, Laura Orío, Isabel Escobedo et al. 57 citations

3,4‐Methylenedioxymethamphetamine (MDMA or ‘ecstasy’) decreases the 5‐HT concentration, [ 3 H]‐paroxetine binding and tryptophan hydroxylase activity in rat forebrain, which has been interpreted as indicating 5‐HT neurodegeneration. This has been questioned, particularly the 5‐HT loss, as MDMA can also inhibit tryptophan hydroxylase. We have now evaluated the validity of these parameters as a...

A study of the role of serotonin in the anxiolytic effect of nitrous oxide in rodents.

Pharmacology, Biochemistry, and Behavior June 1, 2006 Dimitris E Emmanouil, Z Papadopoulou-Daifoti, Philip T Hagihara et al.

In earlier studies, we have shown that nitrous oxide (N2O)-induced behavioral effects in rats and mice are mediated by benzodiazepine receptors. This two-part study was conducted in order to investigate the possible role of serotonin (5-HT) in the behavioral effects of N2O by clarifying its effects on regional brain concentrations of 5-HT and assessing the influence of 5-HT antagonist and...

Recreational ecstasy use and the neurotoxic potential of MDMA: current status of the controversy and methodological issues

Drug and Alcohol Review May 1, 2006 Michael Lyvers 41 citations

The controversy over possible MDMA-induced serotonergic neurotoxicity in human recreational ecstasy users is examined critically in light of recent research findings. Although the designs of such studies have improved considerably since the 1990s, the evidence to date remains equivocal for a number of reasons, including (1) inconsistent findings on the existence and reversibility of persistent...

MDMA and fenfluramine reduce L‐DOPA‐induced dyskinesia via indirect 5‐HT1A receptor stimulation

European Journal of Neuroscience May 1, 2006 Christopher Bishop, Jennifer L. Taylor, Donald M. Kuhn et al. 63 citations

Abstract Chronic l ‐3,4‐dihydroxyphenylalanine (L‐DOPA) pharmacotherapy in Parkinson's disease is often accompanied by the development of abnormal and excessive movements known as dyskinesia. Clinical and experimental studies indicate that indirect serotonin agonists can suppress dyskinesia without affecting the efficacy of L‐DOPA. While the mechanism by which these effects occur is not clear,...

Memory deficits in abstinent MDMA (ecstasy) users: neuropsychological evidence of frontal dysfunction

Journal of Psychopharmacology March 30, 2006 Boris B. Quednow, Frank Jessen, Kai‐uwe Kühn et al. 105 citations

Chronic administration of the common club drug 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) is associated with long-term depletion of serotonin (5-HT) and loss of 5-HT axons in the brains of rodents and non-human primates, and evidence suggests that recreational MDMA consumption may also affect the human serotonergic system. Moreover, it was consistently shown that abstinent MDMA users...

Increased frontal and paralimbic activation following ayahuasca, the pan-amazonian inebriant

Psychopharmacology March 30, 2006 Jordi Riba, Sergio Romero, Eva Grasa et al. 245 citations

RationaleAyahuasca is a South American psychoactive plant tea which contains the serotonergic psychedelic N,N-dimethyltryptamine (DMT) and monoamine-oxidase inhibitors that render DMT orally active. Previous investigations with ayahuasca have highlighted a psychotropic effect profile characterized by enhanced introspective attention, with individuals reporting altered somatic perceptions and...

3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings

Psychopharmacology March 15, 2006 Michael H. Baumann, Xiaoying Wang, Richard B Rothman 269 citations

RATIONALE: 3,4-Methylenedioxymethamphetamine (MDMA) is a widely abused illicit drug. In animals, high-dose administration of MDMA produces deficits in serotonin (5-HT) neurons (e.g., depletion of forebrain 5-HT) that have been interpreted as neurotoxicity. Whether such 5-HT deficits reflect neuronal damage is a matter of ongoing debate. OBJECTIVE: The present paper reviews four specific issues...

Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs

BMC Pharmacology March 3, 2006 Dawn D. Han, Howard H. Gu 419 citations

Abstract Background The plasma membrane neurotransmitter transporters terminate neurotransmissions by the reuptake of the released neurotransmitters. The transporters for the monoamines dopamine, norepinephrine, and serotonin (DAT, NET, and SERT) are targets for several popular psychostimulant drugs of abuse. The potencies of the psychostimulant on the monoamine transporters have been studied...

DOI: 10.1186/1471-2210-6-6 (opens in new tab) MDMA Monoamine neurotransmitter Pharmacology Dopamine transporter +5

Serotonin transporter expression is not sufficient to confer cytotoxicity to 3,4-methylenedioxymethamphetamine (MDMA) in vitro

Journal of Psychopharmacology March 1, 2006 Shaista Hayat, Robert J. Williams, Marcus Rattray

There is much evidence from animal studies that the recreational drug MDMA is a selective toxin which damages serotonin nerve terminals and axons. These in vivostudies show that an interaction between MDMA and the serotonin transporter protein (SERT) is the .rst step in toxicity. To further our understanding of the biochemical processes of MDMA toxicity we wished to use an in vitromodel for...

Pre-treatment with 3,4-methylenedioxymethamphetamine (MDMA) causes long-lasting changes in 5-HT2A receptor-mediated glucose utilization in the rat brain.

Journal of Psychopharmacology March 2006 Eleanor J Bull, Veronica Porkess, Michael Rigby et al.

The current study examined the long-term effect of brief exposure to 3,4-methylenedioxymethamphetamine (MDMA) on local cerebral glucose utilization (LCGU) in specific brain regions immediately following administration of the 5-HT2A/2C receptor agonist, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI). Wistar rats (post-natal day (PND) 28, n = 24) were administered MDMA (5 mg/kg, i.p.) or...

Effects of the N343A mutation in TM6 of the human serotonin 5‐HT2A Receptor

The FASEB Journal March 1, 2006 Michael R Braden, James J. Chambers, David E. Nichols

The human serotonin 2A receptor (h5‐HT 2A R) plays an essential role in cognition, and is the principal target for serotonergic hallucinogens as well as atypical antipsychotics. Utilizing our in silico ‐activated h5‐HT 2A R homology model, an interaction was predicted between Asn343(6.55) in TM6 and the carbonyl of LSD. Virtual docking simulations of a new class of 5‐HT2 agonists, substituted N...

Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects

Journal of Psychopharmacology March 1, 2006 Liesbeth Reneman, Maartje M. L. de Win, Wim van den Brink et al. 85 citations

Users of ecstasy (3,4-methylenedioxymethamphetamine; MDMA) may be at risk of developing MDMA-induced injury to the serotonin (5-HT) system. Previously, there were no methods available for directly evaluating the neurotoxic effects of MDMA in the living human brain. However, development of in vivoneuroimaging tools have begun to provide insights into the effects of ecstasy on the human brain....

DOI: 10.1177/0269881106061515 (opens in new tab) Ecstasy MDMA Serotonin transporter Neuroimaging +3